drugset / Trial / NCT04692831
Testing a New Imaging Agent to Identify Cancer
Phase 1
Active not recruiting
60 enrolled
Memorial Sloan Kettering Cancer Center
National Institutes of Health (NIH) · collab
Non-randomizedParallel-groupOpen-labelDiagnostic
Summary
The purpose of this study is to see whether 89Zr-ss-pertuzumab is safe in people with HER2+ cancer.
Timeline
- Start
- 2020-11-30
- Primary completion
- 2027-11-30
- Completion
- 2027-11-30
Publications
- Yeh R, O'Donoghue JA, Jayaprakasam VS, Mauguen A, Min R, Park S, Brockway JP, Bromberg JF, Zhi WI, Robson ME, Sanford R, Modi S, Agnew BJ, Lyashchenko SK, Lewis JS, Ulaner GA, Zeglis BM. First-in-Human Evaluation of Site-Specifically Labeled 89Zr-Pertuzumab in Patients with HER2-Positive Breast Cancer. J Nucl Med. 2024 Mar 1;65(3):386-393. doi: 10.2967/jnumed.123.266392.
- Zeglis BM, Lewis JS. Click Here for Better Chemistry. N Engl J Med. 2022 Dec 15;387(24):2291-2293. doi: 10.1056/NEJMcibr2213596. Epub 2022 Nov 30. No abstract available.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 89Zr-ss-pertuzumab | Diagnostic / imaging agent | 20 mg | Intravenous |
| Subject | 89Zr-ss-pertuzumab | Diagnostic / imaging agent | 74 mbq | Intravenous |